Roche steps up efficiency drive to take sting out of biosimilars


LONDON/ZURICH (Reuters) – Roche (ROG.S), the world’s biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable.

FILE PHOTO: CEO Severin Schwan of Swiss drugmaker Roche addresses the annual news conference at the company’s headquarters in Base, Switzerland January 28, 2015. REUTERS/Arnd Wiegmann/File Photo

Even though the Swiss company has some of the pharmaceutical industry’s most admired research and development labs, it is now battling to…



Read More Here

Be the first to comment on "Roche steps up efficiency drive to take sting out of biosimilars"

Leave a comment

Your email address will not be published.


*